FOCUS ON INNOVATION: WORKING WITH YOU TO CLOSE THE LOOP IN DIABETES EDUCATION

LETTER FROM THE MEDTRONIC DIABETES CMO

FOCUS ON INNOVATION:

WORKING WITH YOU TO CLOSE THE LOOP IN DIABETES EDUCATION

BY FRANCINE RATNER KAUFMAN, MD

OUR JOURNEY TOGETHER: HELPING YOUR PATIENTS LIVE WITH OPTIMAL DIABETES CARE At Medtronic Diabetes, we focus every day on advancing technology, with the ultimate goal of “closing the loop” for patients with type 1 and type 2 diabetes. With every innovation, we move a step closer to that goal.

Recently, we were thrilled to learn that others are recognizing our progress. The current update to the Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force refers specifically to the MiniMed® 530G with Enlite®, stating: “FDA recently approved a [sensor-augmented pump system] that represents the first step toward an automatic or semiautomatic closed-loop insulin delivery device.”

TODAY’S INNOVATION, TOMORROW’S PATIENT CARE

As with patient education, innovations in technology are evolutionary. Medtronic Diabetes’ leadership in diabetes management and products spans more than 30 years.

During that time, we have achieved a number of milestones:

  • In 1983, we introduced the first MiniMed insulin pump.
  • In 2006, we broke new ground by introducing the first integrated personal continuous glucose monitoring (CGM) and therapy management system.
  • And in 2013, Medtronic’s MiniMed 530G with Enlite, which mimics some of the functionality of a healthy pancreas, became the first—and so far the only—approved device in the Food and Drug Administration’s new artificial pancreas device system (APDS) category.

The MiniMed 530G with Enlite has helped us on the path to fully closed-loop technology, with its sensor-augmented pump therapy and a significant first step in automation with the Threshold Suspend feature to address blood glucose highs and lows. The iterative path to an artificial pancreas includes working toward predictive glucose management and closed-loop technology.

INNOVATION IN EDUCATION

No one knows better than you the importance that diabetes education holds in the optimal treatment of insulin-dependent diabetes. Innovations in education are just as critical as advances in technology.

When we speak of closing the loop in diabetes care, we of course mean in the clinical sense. However, that same concept can apply to diabetes education. By working together and partnering with you and your patients in their lifelong journey of diabetes control, we also can close the loop in diabetes education.

Along with our colleagues at Bayer HealthCare, Medtronic Diabetes has created In the Know as a step toward that goal. As with patient care, you are at the center of this effort. We may have launched this newsletter, but we want you to think of it as yours: A place where you can share information and best practices, successes and struggles, tips and tricks. Greater innovation always comes from collaboration, which benefits everyone involved—especially patients.

SOURCE
Grunberger G, Abelseth JM, Bailey TS, et al. Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force. Endocr Pract. 2014;20(5):463-489. Available at: https://www.aace.com/files/insulin-pump-management-cs.pdf. Accessed April 22, 2015.

Francine Ratner Kaufman, MD, is Chief Medical Officer and VP of Global Clinical, Medical and Health Affairs at Medtronic Diabetes in Northridge, Calif.; a Distinguished Professor Emerita of Pediatrics and Communications at the Keck School of Medicine and the Annenberg School of Communications of the University of Southern California; and an attending physician at Children’s Hospital Los Angeles. Dr. Kaufman has published more than 220 peer-reviewed and invited publications and is the author of more than 40 books or book chapters. In 2012, she authored the Insulin Pump and Glucose Sensor Book for the American Diabetes Association (ADA) and edited the 6th edition of the ADA’s Medical Management of Type 1 Diabetes. In 2005, her book Diabesity was published by Bantam. Dr. Kaufman was chair of the National Institutes of Health-funded Studies to Treat (the TODAY Trial) or Prevent (the HEALTHY Trial) Type 2 Diabetes in Youth (STOPP-T2). Dr. Kaufman has served as president of the American Diabetes Association (2002-03), chair of the National Diabetes Education Program, and chair of the Youth Consultative Section of the International Diabetes Federation. She is a member of the Institute of Medicine and served on the Advisory Council of the NIDDK branch of the NIH. Dr. Kaufman received her Doctorate of Medicine from Chicago Medical School, Chicago, Ill., where she was valedictorian. She completed her internship (Pediatrics), residency (Pediatrics), and fellowship (Pediatric Endocrinology) at Children’s Hospital of Los Angeles, Los Angeles, Calif.